On July 31, 2026, the Health Resources and Services Administration published a revised Notice Regarding the 340B Rebate Model Pilot Program in the Federal Register. The pilot, scheduled to take effect January 1, 2027, would change how manufacturers price drugs to covered entities under the 340B drug discount program.
The change is structural. The program covers an estimated one-third of US hospital drug purchases. Redesigning its pricing mechanics is not an administrative adjustment. It is a shift in how drug revenue flows through a material portion of the US market.
What 340B Is — and What It Does to Access Economics
The 340B program requires drug manufacturers participating in Medicaid to sell outpatient drugs to eligible covered entities — hospitals, federally qualified health centers, Ryan White clinics, and others — at a significant discount, typically 20 to 50 percent below list price. Covered entities then bill payers at higher rates, with the margin supporting the financial viability of safety-net providers.
For manufacturers, 340B participation is not optional if they want Medicaid coverage. But it affects net revenue materially. The channel exists in every commercial model — or should. The question is whether the assumptions built around it are current.
What the Pilot Changes
The revised pilot replaces upfront discounts with retroactive rebates. Under this structure, manufacturers would bill covered entities at list price. Rebates would be calculated and paid after the fact, based on purchasing data verified through the pilot mechanism.
The stated rationale is improved data visibility and program integrity. Hospitals and health systems oppose the change, arguing it removes the immediate revenue that supports care delivery. Legal challenges to earlier iterations of this policy are ongoing.
Whether the pilot survives those challenges is uncertain. The policy direction is not. This is the latest step in a multi-year effort to restructure 340B pricing. The outcome of any single rulemaking does not change the underlying trend.
Market Access Implications
Two implications apply to any asset with covered entity exposure.
First, the commercial math changes. A drug launch modeled on the current upfront-discount structure will produce different revenue projections than one modeled under a rebate system. Revenue timing, covered entity purchasing behavior, and channel economics all shift. Any model that has not been updated for the pilot is working with outdated inputs.
Second, the trend is the signal. US drug pricing is not stable. The sequence of 340B actions — spanning both the current and prior administration — reflects a consistent structural pressure toward transparency and reduced manufacturer obligations. A market access framework that treats current policy as a fixed parameter will produce error, repeatedly.
MARA’s Pricing & Reimbursement Domain
MARA assesses pricing and reimbursement risk as a scored, comparable signal across assets. It is not a scenario label or a sensitivity range added at the back of a model. It is a calibrated input, grounded in policy precedent, applied consistently regardless of therapeutic area or company.
A drug with material covered entity exposure carries 340B policy risk that is now measurably moving. That risk should appear in the asset’s access score — not in a footnote drafted after the regulatory notice is published.
Risk Signal
340B policy risk has been present for years. What has changed is the pace of action and the regulatory mechanism being used. Any portfolio that carries significant covered entity exposure should hold a current, independent pricing-risk assessment — not the internal assumption from a prior commercial plan.
#MarketAccess #HTA #MARArating #340B #DrugPricing #USPolicy
→ mararating.com/market-access-pharma/
→ mararating.com/mara-ratings-list
Source: BioPharma Dive, July 31, 2026 — https://www.biopharmadive.com/news/the-trump-administration-tries-again-340b-rebates/826766/